Patents by Inventor Christiane Opitz

Christiane Opitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER
    Publication number: 20230032216
    Abstract: The present invention relates to the use of Interleukin-4-induced gene 1 (IL4I1) as well as metabolites as produced by IL4I1 as marker in diagnosis and therapy of cancer and related metastasis and/or resistance to immunotherapy.
    Type: Application
    Filed: December 10, 2020
    Publication date: February 2, 2023
    Applicant: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280
    Inventors: Alexander Boehme, Saskia Trump, Luis Felipe Somarribas Patterson, Ahmed Sadik, Christiane A. Opitz
  • ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS
    Publication number: 20220195533
    Abstract: The present disclosure relates to the generation and uses of an improved set of biomarkers that are aryl hydrocarbon receptor (AHR) target genes, designated as “AHR biomarkers.” The AHR biomarkers described herein allow one to efficiently determine AHR activation groups and sub-groups, in particular for an improved classification of tumors. As used herein, AHR activation groups are called “AHR activation signatures”. The AHR biomarkers comprise markers that are important in diagnosis and therapy, for example for selecting patients for treatment with AHR activation modulating interventions, and monitoring of therapy response.
    Type: Application
    Filed: March 28, 2020
    Publication date: June 23, 2022
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS
    Inventors: Christiane A. OPITZ, Ahmed SADIK, Saskia TRUMP, Soumya R. MOHAPATRA, Sascha SCHÄUBLE, Erik FÄSSLER, Luis F. SOMARRIBAS PATTERSON
  • INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AS A BIOMARKER AND USES THEREOF
    Publication number: 20220170096
    Abstract: The present invention relates to a newly identified AHR-activating enzyme and uses thereof as marker in the diagnosis and therapy, for example for selecting patients for treatment with IL4I1-modulating interventions, and monitoring of therapy response.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 2, 2022
    Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, HELMHOLTZ-ZENTRUM FUER UMWELTFORSCHUNG GMBH ? UFZ
    Inventors: Christiane A. OPITZ, Ahmed SADIK, Luis Felipe SOMARRIBAS PATTERSON, Soumya R. MOHAPATRA, Mirja Tamara PRENTZELL, Philipp SECKER, Saskia TRUMP
  • Isotopic methods for measurement of tryptophan and metabolites thereof
    Patent number: 11320438
    Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: May 3, 2022
    Assignees: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITAT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
  • ISOTOPIC METHODS FOR MEASUREMENT OF TRYPTOPHAN AND METABOLITES THEREOF
    Publication number: 20180246118
    Abstract: Tryptophan degradation is a key metabolic pathway controlling immune reactions and evidence suggests that during cancer progression generation of tryptophan metabolites may be fundamental for immune escape promoting the malignant phenotype of cancer cells in an autocrine fashion. The present invention relates to methods of measuring mass tag labelled tryptophan and metabolites thereof and methods using the labelled molecules for monitoring in a subject the effectiveness of a treatment and of disease recurrence after treatment, for stratifying patients and for diagnosing suppression of an immune response in a subject.
    Type: Application
    Filed: October 31, 2016
    Publication date: August 30, 2018
    Applicants: ELECTROPHORETICS LIMITED, RUPRECHT-KARLS-UNIVERSITÄT, DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Sasa Koncarevic, Karsten Kuhn, Peter Schulz-Knappe, Ian Hugo Pike, Christiane Opitz, Michael Platten
  • Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
    Patent number: 9593062
    Abstract: The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 14, 2017
    Assignee: DEUTSCHLAND KREBSFORSCHUNGSZENTRUM
    Inventors: Michael Platten, Christiane Opitz, Wolfgang Wick, Ulrike Litzenburger
  • MEANS AND METHODS FOR TREATING AND/OR PREVENTING NATURAL AHR LIGAND-DEPENDENT CANCER
    Publication number: 20140294860
    Abstract: The present invention relates to the field of cancer therapeutics and treatment of cancer. In particular, it relates to a method for treating and/or preventing a natural AHR ligand-dependent cancer comprising administering to a subject suffering from said cancer a therapeutically effective amount of an AHR inhibitor. Moreover, contemplated is a AHR inhibitor for use in treating and/or preventing a natural AHR ligand-dependent cancer.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 2, 2014
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Michael Platten, Christiane Opitz, Wolfgang Wick, Ulricke Litzenburger